<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-id journal-id-type="hwp">jem</journal-id><journal-title-group><journal-title>The Journal of Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19564354</article-id><article-id pub-id-type="publisher-id">20090547</article-id><article-id pub-id-type="doi">10.1084/jem.20090547</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Cao</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bover</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Minkwon</given-names></name><xref ref-type="aff" rid="aff2">3</xref></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Xiaoxia</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Hanabuchi</surname><given-names>Shino</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bao</surname><given-names>Musheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rosen</surname><given-names>David B.</given-names></name><xref ref-type="aff" rid="aff3">4</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yi-Hong</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>Joanne L.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Qiumei</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Chun</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Arai</surname><given-names>Naoko</given-names></name><xref ref-type="aff" rid="aff2">3</xref></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Zhengbin</given-names></name><xref ref-type="aff" rid="aff4">5</xref></contrib><contrib contrib-type="author"><name><surname>Lanier</surname><given-names>Lewis L.</given-names></name><xref ref-type="aff" rid="aff3">4</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yong-Jun</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Immunology</institution>, <label>2</label><institution>Department of Experimental Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77054</institution></aff><aff id="aff2"><label>3</label><institution>SBI Biotech Co., Ltd., Ginkgo Biomedical Research Institute, Kawasaki 216-0001, Japan</institution></aff><aff id="aff3"><label>4</label><institution>Department of Microbiology and Immunology and the Cancer Research Institute, University of California at San Francisco, San Francisco, CA 94143</institution></aff><aff id="aff4"><label>5</label><institution>Genentech, Inc., South San Francisco, CA 94080</institution></aff><author-notes><corresp>CORRESPONDENCE Wei Cao: <email>wcao@mdanderson.org</email> OR Yong-Jun Liu: <email>yjliu@mdanderson.org</email></corresp><fn><p>D.B. Rosen&#x02019;s present address is Nodality, Inc., South San Francisco, CA 94080.</p></fn></author-notes><pub-date pub-type="ppub"><day>6</day><month>7</month><year>2009</year></pub-date><volume>206</volume><issue>7</issue><fpage>1603</fpage><lpage>1614</lpage><history><date date-type="received"><day>10</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>8</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 Cao et al.</copyright-statement><copyright-year>2009</copyright-year><license license-type="openaccess" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This article is distributed under the terms of an Attribution&#x02013;Noncommercial&#x02013;Share Alike&#x02013;No Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.jem.org/misc/terms.shtml">http://www.jem.org/misc/terms.shtml</ext-link>). After six months it is available under a Creative Commons License (Attribution&#x02013;Noncommercial&#x02013;Share Alike 3.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link>).</license-p></license></permissions><abstract><p>Plasmacytoid dendritic cells (pDCs) produce copious type I interferon (IFN) upon sensing nucleic acids through Toll-like receptor (TLR) 7 and TLR9. Uncontrolled pDC activation and IFN production are implicated in lymphopenia and autoimmune diseases; therefore, a mechanism controlling pDC IFN production is essential. Human pDCs specifically express an orphan receptor, immunoglobulin-like transcript 7 (ILT7). Here, we discovered an ILT7 ligand expressed by human cell lines and identified it as bone marrow stromal cell antigen 2 (BST2; CD317). BST2 directly binds to purified ILT7 protein, initiates signaling via the ILT7&#x02013;Fc&#x003f5;RI&#x003b3; complex, and strongly inhibits production of IFN and proinflammatory cytokines by pDCs. Readily induced by IFN and other proinflammatory cytokines, BST2 may modulate the human pDC&#x02019;s IFN responses through ILT7 in a negative feedback fashion.</p></abstract></article-meta></front><body><p>In humans and other mammals, plasmacytoid DCs (pDCs) are specialized immune cells that selectively express Toll-like receptor (TLR) 7 and TLR9, which are key endosomal sensors of microbial and self-RNA or DNA, respectively (<xref ref-type="bibr" rid="bib32">Jarrossay et al., 2001</xref>; <xref ref-type="bibr" rid="bib33">Kadowaki et al., 2001</xref>; <xref ref-type="bibr" rid="bib41">Liu, 2005</xref>; <xref ref-type="bibr" rid="bib26">Gilliet et al., 2008</xref>). Activation of TLR7 or TLR9 by nucleic acids in pDCs triggers signal transduction, leading to rapid and robust secretion of type I IFN, inflammatory cytokines, and chemokines (<xref ref-type="bibr" rid="bib15">Colonna et al., 2004</xref>; <xref ref-type="bibr" rid="bib31">Honda and Taniguchi, 2006</xref>; <xref ref-type="bibr" rid="bib36">Kawai and Akira, 2006</xref>; <xref ref-type="bibr" rid="bib52">Piqueras et al., 2006</xref>; <xref ref-type="bibr" rid="bib26">Gilliet et al., 2008</xref>). The TLR-induced IFN response is regulated by several immunoreceptor tyrosine-based activation motif (ITAM)&#x02013;bearing signaling receptors on pDCs (<xref ref-type="bibr" rid="bib50">Novak et al., 2004</xref>; <xref ref-type="bibr" rid="bib25">Fuchs et al., 2005</xref>; <xref ref-type="bibr" rid="bib5">Blasius et al., 2006a</xref>; <xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>, <xref ref-type="bibr" rid="bib9">2007</xref>; <xref ref-type="bibr" rid="bib53">R&#x000f6;ck et al., 2007</xref>; <xref ref-type="bibr" rid="bib14">Cho et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">Gilliet et al., 2008</xref>). One such receptor is ILT7, a member of the Ig-like transcript (ILT) family (also known as leukocyte Ig-like receptors) found in humans and primates (<xref ref-type="bibr" rid="bib7">Brown et al., 2004</xref>).</p><p>ILTs, which are expressed by a variety of immune cell types, are comprised of a group of inhibitory receptors bearing immunoreceptor tyrosine-based inhibitory motifs and a group of stimulatory receptors that signal through their association with adaptor molecules containing ITAM (<xref ref-type="bibr" rid="bib7">Brown et al., 2004</xref>). ILT7, also known as LILRA4 and CD85g, contains four extracellular Ig-like domains and a positively charged residue within the transmembrane region, allowing ILT7 to form a receptor complex with a signaling adaptor Fc<italic>&#x003f5;</italic>RI&#x003b3;. Uniquely expressed by human pDCs, ILT7 suppresses TLR7/9-induced type I IFN secretion by pDCs when cross-linked by anti-ILT7 mAbs that trigger signaling activation (<xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>; <xref ref-type="bibr" rid="bib14">Cho et al., 2008</xref>). Although several members of the inhibitory ILT family regulate innate and adaptive immune responses through interaction with classical and nonclassical MHC class I ligands or virus-encoded MHC class I&#x02013;like proteins (<xref ref-type="bibr" rid="bib13">Chapman et al., 1999</xref>; <xref ref-type="bibr" rid="bib7">Brown et al., 2004</xref>), the natural ligands for the stimulatory ILTs, including ILT7, are unknown.</p><p>Here, we report the identification of a surface molecule named bone marrow stromal cell antigen 2 (BST2) as a biological ligand for ILT7 and provide evidence that BST2&#x02013;ILT7 engagement may serve as a force to negatively regulate human pDCs&#x02019; innate immune functions, likely during inflammation, in a negative feedback manner.</p><sec sec-type="results"><title>RESULTS</title><sec><title>Human cancer cells express novel ILT7 ligand</title><p>Previously, we constructed an NFAT-GFP reporter cell line expressing ILT7 and Fc<italic>&#x003f5;</italic>RI&#x003b3; that expresses GFP in response to ILT7 surface ligation (<xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>). To detect the presence of ILT7 ligands (ILT7-L), we used these cells to screen virus-infected cells and a large panel of human tumor cell lines. Co-culture of the ILT7 reporter cells with human breast carcinoma MDA-MB-468, MCF7, and T47D cells, but not with MDA-MB-231 or ZR-75-1 cells, induced GFP expression by the reporter cells (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>). We further tested several human ovarian, colon, melanoma, glioma, and lung cancer cell lines and found that two melanoma lines, WM35 and Mel938, were able to similarly activate the ILT7 reporter cells (<xref ref-type="fig" rid="fig1">Fig. 1 B</xref>). Other transformed cell lines, such as HEK293, Vero, CHO, Cos7, and Jurkat, were unable to stimulate the ILT7 reporter cells (unpublished data).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><p><bold>Human tumor cell lines express a potential ligand for ILT7.</bold> (A) Five human breast cancer cell lines were co-cultured with either ILT7<sup>+</sup> NFAT-GFP reporter cells or parental NFAT-GFP reporter cells. The percentages of GFP-positive reporter cells were analyzed. Data are representative of four independent experiments. (B) Human carcinoma cells were co-cultured with ILT7<sup>+</sup> NFAT-GFP reporter cells. The percentages of GFP-positive reporter cells were analyzed. The categories of the cancer lines are as follows: OVCAR-3, SKOV-3, and DOV-13 (ovarian); HT-29 and HCT-116 (colon); WM35, WM239, MEL526, MEL624, MEL888, and MEL938 (melanoma); U87, LN229, and SNB19 (glioblastoma); A549 (lung cancer). Data are representative of two independent experiments. (C) T47D cells were co-cultured with ILT7<sup>+</sup> NFAT-GFP reporter cells in the presence of 1 &#x000b5;g/ml of control IgG1 or anti-ILT7 mAb. The percentages of GFP-positive reporter cells were plotted. Data are representative of four independent experiments. (D) Breast cancer MDA-MB-468 cells were first cultured for 5 d in the presence of medium, 5 ng/ml of TNF-&#x003b1; or 500 U/ml of IFN-&#x003b1;, and then co-cultured with NFAT-GFP reporter cells. The percentages of GFP-positive reporter cells were analyzed. Data are representative of four independent experiments. Error bars represent the mean &#x000b1; the SEM.</p></caption><graphic xlink:href="JEM_20090547_GS_Fig1"/></fig><p>As the breast cancer line T47D is most potent in triggering ILT7, we further characterized these cells. The ability of T47D cells to activate the reporter cells is ILT7 dependent because NFAT-GFP reporter cells expressing only the signaling adaptor Fc<italic>&#x003f5;</italic>RI&#x003b3;, and not ILT7, were not activated (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>). In addition, the induction of GFP was completely abolished by a neutralizing anti-ILT7 mAb (<xref ref-type="fig" rid="fig1">Fig. 1 C</xref>). Pretreatment with IFN-&#x003b1; and TNF-&#x003b1; enhanced the ability of the breast cancer MDA-MB-468 cells to activate the ILT7 reporters (<xref ref-type="fig" rid="fig1">Fig. 1 D</xref>), suggesting that ILT7-L expression is regulated by immune responses.</p><p>ILT7 activation by cancer cells requires direct cell&#x02013;cell contact as cells cultured in separate chambers of a transwell dish fail to induce GFP (unpublished data). Although the two other ILT family members, ILT2 and ILT4, bind to the classical and nonclassical MHC class I (MHC-I) ligands (<xref ref-type="bibr" rid="bib47">Navarro et al., 1999</xref>; <xref ref-type="bibr" rid="bib7">Brown et al., 2004</xref>), the putative ILT7-L appears to be unrelated to MHC class I or class II because antibodies against human MHC class I or class II did not block the ability of T47D cells to activate the ILT7 reporter cells (unpublished data), and both the MHC class I&#x02013;expressing cell lines (e.g., Jurkat and MDA-MB-231) and the MHC class II&#x02013;expressing cell lines (e.g., EBV-transformed B cells) were unable to activate ILT7 reporter cells (unpublished data).</p></sec><sec><title>Identification of ILT7-L</title><p>To facilitate the identification of the putative ILT7-L, we immunized mice with T47D (ILT7-L<sup>pos</sup>) and MDA-MB-231 (ILT7-L<sup>neg</sup>) cells and obtained multiple hybridoma clones that bound specifically to T47D cells, but not to MDA-MB-231 cells. To identify mAbs that specifically recognize ILT7-L, we further screened the hybridoma clones for the ability to block T47D-induced ILT7 reporter cell activation. Two such clones (26F8 and 28G4) were identified (<xref ref-type="fig" rid="fig2">Fig. 2 A</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><p><bold>Characterization of mAbs against a putative ILT7 ligand.</bold> (A) Culture supernatants from different hybridoma clones were included in the co-cultures of ILT7 reporter cells and T47D cells. The percentages of GFP-positive reporter cells were determined. Two clones able to inhibit GFP induction are indicated (arrows). Anti-ILT7 mAb (clone 17.2) was included as a positive control. (B) Five human breast cancer cells were stained with mAb 26F8 (red line) or an isotype-matched control mAb (shaded area) and analyzed by flow cytometry. A similar result obtained with mAb 28G4 is not shown. Data are representative of three independent experiments. (C) T47D cells were co-cultured with ILT7 reporter cells in the presence of control IgG1, 26F8, or 28G4 mAbs at different concentrations. The percentages of GFP-positive reporter cells were plotted. Data are representative of four independent experiments. (D) Surface biotinylated MDA-MB-231 and T47D were immunoprecipitated with control IgG1, 26F8, or 28G4. The precipitated proteins were analyzed by Western blotting with NeutrAvidin-HRP. Arrows indicate the specific protein bands obtained from T47D cells. Data are representative of two independent experiments.</p></caption><graphic xlink:href="JEM_20090547_RGB_Fig2"/></fig><p>Using flow cytometry, we found that these two mAbs stained the breast tumor cell lines MDA-MB-468, MCF7, and T47D, which activated ILT7 reporter cells, but minimally reacted with breast tumor cell lines MDA-MB-231 and ZR-75-1, which failed to activate ILT7 reporters (<xref ref-type="fig" rid="fig2">Fig. 2 B</xref>). Other cell lines (e.g., HEK293, Vero, CHO, and Cos 7) that failed to activate the ILT7 reporter cells were not stained by either 26F8 or 28G4 (unpublished data). In addition, these two mAbs, but not the isotype-matched control mAb, strongly inhibited the ability of the tumor cell line T47D to activate the ILT7 reporter cells in a dose-dependent fashion (<xref ref-type="fig" rid="fig2">Fig. 2 C</xref>). The two mAbs recognize nonoverlapping epitopes, because one did not block the binding of the other to T47D cells, as determined by flow cytometry (unpublished data). Nevertheless, 26F8 and 28G4 mAbs immunoprecipitated three similar protein bands in T47D cells, but not in MDA-MB-231 cells (<xref ref-type="fig" rid="fig2">Fig. 2 D</xref>), suggesting the presence of cellular proteins as the potential ligand for ILT7.</p><p>To identify the ligand for ILT7, 26F8 and 28G4 mAbs were used to screen a human cDNA library. Both antibodies specifically recognized the gene product of human BST2 (CD317). BST2 is a 180-aa glycoprotein that was initially identified as a membrane protein expressed by bone marrow stromal cells and later shown to be expressed by plasma cells and multiple types of cancer cells (<xref ref-type="bibr" rid="bib51">Ohtomo et al., 1999</xref>; <xref ref-type="bibr" rid="bib37">Kupzig, 2003</xref>; <xref ref-type="bibr" rid="bib64">Walter-Yohrling et al., 2003</xref>). BST2 is reportedly expressed on many different types of cells after exposure to IFN-&#x003b1; (<xref ref-type="bibr" rid="bib6">Blasius et al., 2006b</xref>; <xref ref-type="bibr" rid="bib48">Neil et al., 2008</xref>; <xref ref-type="bibr" rid="bib62">Van Damme et al., 2008</xref>).</p></sec><sec><title>BST2 is an ILT7 ligand</title><p>The 26F8 and 28G4 mAbs stained the human BST2 cDNA-transfected HEK293 cells, but not mock-transfected cells, by flow cytometry (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). In addition, recombinant ILT7 protein directly bound to a recombinant BST2-GST fusion protein, but not GST protein, in a dose-dependent manner (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>). Specific interaction between recombinant BST2-Fc and ILT7-Fc with an estimated affinity of &#x0223c;10<sup>&#x02212;6</sup> M was detected by surface plasma resonance with Biacore, an interaction that was completely neutralized by 26F8 mAb (<xref ref-type="fig" rid="fig3">Fig. 3 C</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><p><bold>BST2 directly binds to ILT7.</bold> (A) HEK293 cells transiently transfected with mock control or BST2 cDNA were analyzed by Western blotting for BST2 protein expression. Transfected cells were stained with 26F8 mAb and analyzed by flow cytometry. The staining profile with IgG isotype-matched control mAb is shown in the shaded area. Staining with 28G4 mAb produced identical results (not depicted). Data are representative of five independent experiments. (B) Plate-coated GST or BST2-GST were incubated with different concentrations of recombinant ILT7-Fc and HRP-conjugated anti&#x02013;human Fc. Shown is absorption at OD 450 nm for each sample after addition of Tetramethyl benzidine (TMB) substrate. Data are representative of three independent experiments. (C, top) Recombinant BST2-Fc, precoated on the surface of Biacore sensor chips, was mixed with different concentrations of injected recombinant ILT7-Fc. The kinetic response data after subtracting the value from precoated Fc are shown. Also shown are control responses with Fc alone or buffer. (bottom) Precoated recombinant BST2-Fc was premixed with buffer, control IgG1, or anti-BST2 mAb 26F8 and then exposed to injected recombinant ILT7-Fc. The kinetic response data after subtracting the value from precoated Fc are shown. Data are representative of two independent experiments.</p></caption><graphic xlink:href="JEM_20090547_RGB_Fig3"/></fig><p>Furthermore, rBST2-GST fusion protein, but not GST alone, strongly activated the ILT7 reporter cells (<xref ref-type="fig" rid="fig4">Fig. 4 A</xref>). The specificity of the BST2&#x02013;ILT7 interaction was demonstrated by the findings that rBST2-GST failed to induce GFP expression in ILT7-negative reporter cells and that BST2-induced GFP expression in the ILT7 reporter cells was abrogated by neutralizing antibodies against either ILT7 or BST2, but not by control antibody. More importantly, BST2 expressed on the surface of HEK293 cells induced GFP expression in ILT7 reporter cells, but not in ILT7-negative reporter cells. Again, activation of the ILT7 reporter was blocked by neutralizing antibodies against either ILT7 or BST2 (<xref ref-type="fig" rid="fig4">Fig. 4 B</xref>). These data identify BST2 as a physiological ligand that specifically binds and activates ILT7.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><p><bold>BST2 binds and potently activates ILT7.</bold> (A) GST or BST2-GST protein was co-cultured with ILT7<sup>+</sup> NFAT-GFP reporter cells. The percentages of GFP-positive reporter cells are shown. Neutralizing antibodies &#x003b1;ILT7 (5 &#x000b5;g/ml) or 26F8 (25 &#x000b5;g/ml) or an IgG1 control antibody were included in the cultures, as indicated. Data are representative of four independent experiments. (B) HEK293 cells transiently transfected with mock control or BST2 cDNA were co-cultured with ILT7<sup>+</sup> NFAT-GFP reporter cells. The percentages of GFP<sup>+</sup> reporter cells are shown. Neutralizing antibodies &#x003b1;ILT7 (5 &#x000b5;g/ml), 26F8 (25 &#x000b5;g/ml), 28G4 (25 &#x000b5;g/ml), or control IgG1 were included in the cultures, as indicated. Data are representative of three independent experiments.</p></caption><graphic xlink:href="JEM_20090547_RGB_Fig4"/></fig></sec><sec><title>BST2 negatively regulates the innate immune functions of human pDCs</title><p>As previously shown, antibody cross-linking of ILT7 can induce prominent calcium influx in primary pDCs as a result of ITAM-mediated Fc&#x003f5;RI&#x003b3; signaling (<xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>; <xref ref-type="bibr" rid="bib14">Cho et al., 2008</xref>). Similarly, a rBST2-Fc protein, but not a control Fc protein alone, induced calcium mobilization in human pDCs, which depends on the function of Syk (<xref ref-type="fig" rid="fig5">Fig. 5 A</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><p><bold>BST2 activates primary pDCs and inhibits IFN and cytokine production by pDCs.</bold> (A) pDCs were incubated with anti-ILT7, recombinant Fc, or BST2-Fc proteins and then analyzed for calcium influx. pDCs pretreated with 5 &#x000b5;M of Syk inhibitor were also analyzed. Data are representative of three independent experiments. (B) The amounts of secreted cytokines from pDCs cultured with plate-bound Fc or BST2-Fc are shown. pDCs were activated overnight with either 0.2 &#x000b5;M of CpG 2216 or MOI 6 of Flu. Data are representative of five independent experiments with ten donors. (C) The levels of gene transcripts from pDCs cultured with purified Fc or BST2-Fc are shown. The relative expression of each gene was normalized with S18 and calculated against the value obtained from normal total PBMCs. Data are representative of two independent experiments. (D) BST2 does not affect co-stimulatory molecule expression by pDCs. pDCs cultured with plate-bound Fc or BST2-Fc and then activated with 0.2 &#x000b5;M of CpG 2216 for 48 h. Surface levels of CD80 and CD86 are shown. Data are representative of two independent experiments. (E) pDCs preincubated with medium, 20 &#x000b5;g/ml of IgG1 or 20 &#x000b5;g/ml of neutralizing ILT7 mAb were cultured overnight with plate-bound Fc or BST2-Fc in the presence of CpG 2216. The amounts of secreted IFN-&#x003b1; were measured by ELISA. Percent of BST2-mediated IFN-&#x003b1; suppression was calculated as percent ratio of IFN-&#x003b1; ([Fc minus BST2-Fc]/[Fc]) and plotted. Data are representative of two independent experiments with four donors. (F) The amounts of secreted IFN-&#x003b1; from Flu-challenged pDCs cultured with HEK293 with or without surface HA-tagged BST2 are shown. Data are representative of two independent experiments.</p></caption><graphic xlink:href="JEM_20090547_RGB_Fig5"/></fig><p>Because mAb cross-linking of ILT7 inhibits the immune response of pDCs, we investigated the effect of BST2 on TLR-induced cytokine responses by pDCs. Freshly isolated pDCs from human peripheral blood were preincubated with plate-bound rBST2-Fc protein or plate-bound Fc protein for 30 min, and were then challenged with influenza virus (Flu) or CpG, which trigger TLR7 and TLR9, respectively. rBST2 protein suppressed the secretion of IFN-&#x003b1; and TNF-&#x003b1; (<xref ref-type="fig" rid="fig5">Fig. 5 B</xref>), as well as the transcription of type I IFN subtypes, including IFN&#x003b1;1, IFN&#x003b1;4, IFN&#x003b1;8, and IFN-&#x003b2;, plus IL-6, by pDCs (<xref ref-type="fig" rid="fig5">Fig. 5 C</xref>) when activated by TLR agonists. In contrast, BST2 did not alter expression of co-stimulatory molecules, such as CD80 and CD86, by pDCs (<xref ref-type="fig" rid="fig5">Fig. 5, C and D</xref>). The effect of BST2-mediated IFN suppression was abolished when ILT7 was neutralized with anti-ILT7 mAb, but not with control IgG1, indicating a direct engagement between ILT7 and rBST2 (<xref ref-type="fig" rid="fig5">Fig. 5 E</xref>). Lastly, pDCs co-cultured with HEK293 cells expressing an HA-tagged BST2 secreted reduced levels of IFN-&#x003b1; in response to Flu virus when compared with pDCs in contact with untransfected HEK293 cells (<xref ref-type="fig" rid="fig5">Fig. 5 F</xref>), suggesting that the BST2&#x02013;ILT7 interaction modulates pDCs&#x02019; TLR-induced IFN responses.</p></sec><sec><title>BST2 expression by human cells and by pDCs</title><p>To understand the prevalence of BST2 expression on human cells in response to IFN treatment, we cultured embryonic kidney HEK293 cells, dermal fibroblast line NHDF cells, human umbilical vein endothelial line HUVEC cells, and keratinocyte line HaCat cells in the absence or presence of IFN-&#x003b1;, and then analyzed BST2 surface expression by flow cytometry (<xref ref-type="fig" rid="fig6">Fig. 6 A</xref>). Although these cells minimally express BST2 under normal conditions, IFN-&#x003b1; treatment resulted in significant surface BST2 expression in all of them, which is consistent with the reported IFN-mediated BST2 induction (<xref ref-type="bibr" rid="bib6">Blasius et al., 2006b</xref>; <xref ref-type="bibr" rid="bib48">Neil et al., 2008</xref>; <xref ref-type="bibr" rid="bib62">Van Damme et al., 2008</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><p><bold>Analysis of BST2 expression and potential BST2&#x02013;ILT7 cis-interaction.</bold> (A) HEK293, NHDF, HUVEC, and HaCat cells, cultured in the absence or presence of 500 units/ml of IFN-&#x003b1; for 48 h, were stained with anti-BST2 mAb 26F8. Staining with isotype-matched control Ig is shown in the gray shaded area. Data are representative of three independent experiments. (B) Fresh isolated pDCs from peripheral blood or cells activated with various stimuli for 48 h were analyzed for surface BST2 expression by flow cytometry. Data are representative of two independent experiments. (C) Human Burkitt&#x02019;s lymphoma Namalwa cells transduced with different pDC receptor complexes, i.e., BDCA2/Fc&#x003f5;RI&#x003b3; or ILT7/Fc&#x003f5;RI&#x003b3;, were analyzed for surface BST2 and ILT7 expression. Data are representative of three independent experiments.</p></caption><graphic xlink:href="JEM_20090547_RGB_Fig6"/></fig><p>Interestingly, resting mouse pDCs prominently express BST2 (<xref ref-type="bibr" rid="bib6">Blasius et al., 2006b</xref>), but lack the expression of a direct orthologue of ILT7 (<xref ref-type="bibr" rid="bib7">Brown et al., 2004</xref>). However, low amounts of surface BST2 were detected on human pDCs that were freshly isolated or cultured with either TLR ligands or cytokines (<xref ref-type="fig" rid="fig6">Fig. 6 B</xref>), although BST2 transcripts were found elevated in TLR-activated pDCs (unpublished data). To investigate a potential cis interaction between ILT7 and BST2, we transduced ILT7 and Fc&#x003f5;RI&#x003b3; into a human Burkitt&#x02019;s lymphoma cell line expressing endogenous BST2. Interestingly, expression of the ILT7&#x02013;Fc&#x003f5;RI&#x003b3; complex, but not BDCA2&#x02013;Fc&#x003f5;RI&#x003b3;, another human pDC-specific receptor complex, reduced the levels of surface BST2 (<xref ref-type="fig" rid="fig6">Fig. 6 C</xref>). Thus, ILT7&#x02013;BST2 cis interaction likely results in BST2 internalization and might have functional consequences in human pDCs.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Here, we identify BST2 as a physiological ligand for a human pDC-specific receptor ILT7. pDCs play a critical role in antiviral innate immune responses by secreting large quantities of IFN-&#x003b1;/&#x003b2;. However, the type 1 IFN responses immediately after viral infection are short lived; if not, massive and prolonged IFN exposure will damage hematopoiesis, leading to lymphopenia (<xref ref-type="bibr" rid="bib40">Lin et al., 1998</xref>; <xref ref-type="bibr" rid="bib34">Kamphuis et al., 2006</xref>), and increase the risk of autoimmunity (<xref ref-type="bibr" rid="bib27">Gota and Calabrese, 2003</xref>). Hence, a mechanism ensuring a specific and transient IFN response to viruses is critical to minimize the possibility of lymphopenia and autoimmune diseases in the host. As BST2 is well known to be robustly induced on the surface of various types of cells after exposure to IFN and other proinflammatory cytokines via STAT activation (<xref ref-type="bibr" rid="bib51">Ohtomo et al., 1999</xref>; <xref ref-type="bibr" rid="bib6">Blasius et al., 2006b</xref>; <xref ref-type="bibr" rid="bib48">Neil et al., 2008</xref>; <xref ref-type="bibr" rid="bib62">Van Damme et al., 2008</xref>), the BST2&#x02013;ILT7 interaction, therefore, likely serves as an important negative feedback mechanism for preventing prolonged IFN production after viral infection (<xref ref-type="fig" rid="fig7">Fig. 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><p><bold>A proposed model of BST2&#x02013;ILT7 mediated regulation of pDC innate immune responses.</bold> (top) By sensing viral infection, pDCs can rapidly and rigorously produce large amounts of IFN-I via TLR7 or TLR9 activation. IFN-I then may induce the neighboring cells to express BST2, which in turn engages with ILT7 on pDCs to down-regulate the magnitude of IFN and cytokine responses in a negative feedback manner. (bottom) In a tumor environment where BST2 is endogenously expressed, infiltrating pDCs may be functionally suppressed to elicit normal IFN response to TLR ligands as a result of BST2&#x02013;ILT7 interaction.</p></caption><graphic xlink:href="JEM_20090547_RGB_Fig7"/></fig><p>Intracellular TLRs have limited ability to discriminate host versus foreign nucleic acids (<xref ref-type="bibr" rid="bib28">Haas et al., 2008</xref>). Several host factors, including anti-DNA antibodies, antimicrobial peptide LL37, or the nuclear DNA-binding protein HMGB1, alone or in combination, facilitate entry of self-DNA into the endosomes of pDCs, where they trigger TLR9 to induce type 1 IFN responses (<xref ref-type="bibr" rid="bib38">Lande et al., 2007</xref>; <xref ref-type="bibr" rid="bib43">Marshak-Rothstein and Rifkin, 2007</xref>; <xref ref-type="bibr" rid="bib60">Tian et al., 2007</xref>). Similarly, autoantibody&#x02013;self small nuclear ribonucleoprotein complexes can activate TLR7 through Fc&#x003b3;RII to induce IFN (<xref ref-type="bibr" rid="bib63">Vollmer et al., 2005</xref>; <xref ref-type="bibr" rid="bib55">Savarese et al., 2006</xref>). This might lead to the constitutive activation of pDCs, which contributes to the autoimmune pathology of systemic lupus erythematosus and psoriasis. It will be of further interest to study if the BST2&#x02013;ILT7&#x02013;mediated controlling mechanism is breached in patients with systemic lupus erythematosus and psoriasis (<xref ref-type="bibr" rid="bib4">Blanco et al., 2001</xref>; <xref ref-type="bibr" rid="bib38">Lande et al., 2007</xref>; <xref ref-type="bibr" rid="bib43">Marshak-Rothstein and Rifkin, 2007</xref>), which may provide an opportunity to develop therapeutics to down-modulate pDC activation during autoimmune disease.</p><p>Interestingly, BST2 represents the first non&#x02013;MHC class I&#x02013;type ligand for a member of the ILT receptor family (<xref ref-type="bibr" rid="bib7">Brown et al., 2004</xref>). By sequence analysis, human receptor ILTs are divided into two separate groups&#x02014;five inhibitory ILTs containing intracellular immunoreceptor tyrosine-based inhibitory motifs and six stimulatory ILTs that would couple with ITAM-bearing adaptors. The inhibitory ILTs, e.g., ILT2 and ILT4, recognize proteins encoded by many MHC class I alleles and UL18, which is a MHC-like molecule associated with human cytomegalovirus (<xref ref-type="bibr" rid="bib13">Chapman et al., 1999</xref>). However, the ligands for the stimulatory group of ILTs are largely unknown (<xref ref-type="bibr" rid="bib16">Cosman et al., 1997</xref>; <xref ref-type="bibr" rid="bib7">Brown et al., 2004</xref>). Structural analysis revealed significant differences in MHC class I&#x02013;binding sites between the inhibitory and stimulatory ILTs (<xref ref-type="bibr" rid="bib56">Shiroishi et al., 2006</xref>), suggesting distinct ligand recognition by the two groups of ILTs. Here, we used a NFAT-GFP reporter cell system that reliably senses ILT7 surface ligation in the presence of an ILT7 ligand, which led to the positive identification of BST2, a glycoprotein unrelated to the MHC molecules. BST2 protein has a unique topology, containing an N-terminal transmembrane domain and a C-terminal GPI anchor, and locates within the lipid raft microdomains on plasma membrane (<xref ref-type="bibr" rid="bib37">Kupzig, 2003</xref>). Further structural analysis of the binding interface between BST2 and ILT7 may shed light on the structural basis of ligand recognition by ILT7 and stimulatory ILTs. The receptor-NFAT reporter system should be also useful for the identification of the relevant ligands for other ILT orphan receptors and a better understanding of ILT&#x02019;s biological function.</p><p>As the innate immune system has widely adopted &#x0201c;paired receptors&#x0201d; to exert tight regulatory control, many of the inhibitory receptors participate in self tolerance by recognizing ubiquitously expressed endogenous molecules, whereas stimulatory receptors may recognize &#x0201c;alert&#x0201d; molecules that are up-regulated after viral infection or immune activation (<xref ref-type="bibr" rid="bib39">Lanier, 2008</xref>; <xref ref-type="bibr" rid="bib66">Yamada and McVicar, 2008</xref>). For example, Ly49A, a prototype inhibitory Ly49 receptor expressed on mouse NK cells, recognizes endogenous MHC-I molecule H-2D<sup>d</sup> (<xref ref-type="bibr" rid="bib35">Karlhofer et al., 1992</xref>), whereas stimulatory NK receptor Ly49H binds to glycoprotein M157 encoded by mouse cytomegalovirus (<xref ref-type="bibr" rid="bib1">Arase et al., 2002</xref>; <xref ref-type="bibr" rid="bib58">Smith et al., 2002</xref>), Ly49P recognizes the H-2D<sup>k</sup>&#x02013;restricted mouse cytomegalovirus&#x02013;infected cells (<xref ref-type="bibr" rid="bib19">Desrosiers et al., 2005</xref>), and NKG2D interacts with ligands with structural homology with MHC class I, including RAE-1&#x003b1;-&#x003f5;, H60, and MULT1 (<xref ref-type="bibr" rid="bib11">Cerwenka et al., 2000</xref>; <xref ref-type="bibr" rid="bib21">Diefenbach et al., 2001</xref>, <xref ref-type="bibr" rid="bib22">2003</xref>; <xref ref-type="bibr" rid="bib10">Carayannopoulos et al., 2002</xref>), expression of which is under control of TLR activation, viral infections, and stress (<xref ref-type="bibr" rid="bib42">Lodoen et al., 2003</xref>; <xref ref-type="bibr" rid="bib29">Hamerman et al., 2004</xref>; <xref ref-type="bibr" rid="bib49">Nice et al., 2009</xref>). In human, NKG2D engages with MHC class I&#x02013;like molecules MICA and MICB (<xref ref-type="bibr" rid="bib2">Bauer et al., 1999</xref>), inducible by cell stress, and ULBP1-4 (<xref ref-type="bibr" rid="bib17">Cosman et al., 2001</xref>; <xref ref-type="bibr" rid="bib12">Chalupny et al., 2003</xref>), expression of which is influenced by TLR activation or viral infections (<xref ref-type="bibr" rid="bib24">Ebihara et al., 2007</xref>). The fact that BST2 is a gene product whose expression is under control of inflammatory signals is consistent with the notion that stimulatory receptors may regulate immune functions by interacting with inducible or pathogen-associated ligands.</p><p>Like NK cells, pDCs express both inhibitory receptors and stimulatory receptors. Human pDC receptors ILT7, BDCA2, high-affinity Fc receptor for IgE, and NKp44, which all signal through an ITAM-mediated pathway, exert negative effects on the pDC&#x02019;s IFN response to TLR activation (<xref ref-type="bibr" rid="bib23">Dzionek et al., 2001</xref>; <xref ref-type="bibr" rid="bib50">Novak et al., 2004</xref>; <xref ref-type="bibr" rid="bib25">Fuchs et al., 2005</xref>; <xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>, <xref ref-type="bibr" rid="bib9">2007</xref>). Similarly, activation of Siglec-H, in association with the ITAM-bearing DAP12 subunit, reduces type I IFN production by mouse pDCs in vitro and in vivo (<xref ref-type="bibr" rid="bib5">Blasius et al., 2006a</xref>). On the other hand, Ly49Q, an inhibitory Ly49 receptor expressed on mouse pDCs, recognizes MHC class I molecules and enhances pDC&#x02019;s innate immune responses (<xref ref-type="bibr" rid="bib59">Tai et al., 2008</xref>). Thus, it appears that the so-called stimulatory receptors may exercise potent suppressive regulatory functions on the innate immunity of pDCs.</p><p>Immature pDCs have been found in the local tumor environment of patients with ovarian cancer (<xref ref-type="bibr" rid="bib68">Zou et al., 2001</xref>; <xref ref-type="bibr" rid="bib65">Wei et al., 2005</xref>), breast cancer (<xref ref-type="bibr" rid="bib61">Treilleux et al., 2004</xref>), melanoma (<xref ref-type="bibr" rid="bib54">Salio et al., 2003</xref>; <xref ref-type="bibr" rid="bib3">Benitez-Ribas et al., 2006</xref>), leukemia (<xref ref-type="bibr" rid="bib45">Mohty et al., 2001</xref>, <xref ref-type="bibr" rid="bib46">2004</xref>), Kaposi&#x02019;s sarcoma (<xref ref-type="bibr" rid="bib18">Della Bella et al., 2006</xref>), and head and neck squamous cell carcinoma (<xref ref-type="bibr" rid="bib30">Hartmann et al., 2003</xref>). Although pDCs only infiltrate 13% of primary breast tumors, their presence strongly correlates with an adverse outcome of the disease (<xref ref-type="bibr" rid="bib61">Treilleux et al., 2004</xref>). The breast cancer microenvironment profoundly inhibits pDC&#x02019;s innate immune functions (<xref ref-type="bibr" rid="bib57">Sisirak et al., 2008</xref>). Because IFN-&#x003b1; is well known to be required for deterring the growth of primary tumors (<xref ref-type="bibr" rid="bib69">Wenzel et al., 2005</xref>; <xref ref-type="bibr" rid="bib22">Dunn et al., 2006</xref>), BST2&#x02013;ILT7 interactions that suppress pDCs&#x02019; IFN responses may contribute to the tumor tolerance (<xref ref-type="fig" rid="fig7">Fig. 7</xref>). On the other hand, BST2 found in multiple cancer types was identified as a potent inducer of NF-&#x003ba;B (<xref ref-type="bibr" rid="bib44">Matsuda et al., 2003</xref>) and one of the candidate genes expressed in malignant cells that promote tumor invasion (<xref ref-type="bibr" rid="bib51">Ohtomo et al., 1999</xref>; <xref ref-type="bibr" rid="bib37">Kupzig, 2003</xref>; <xref ref-type="bibr" rid="bib64">Walter-Yohrling et al., 2003</xref>). Thus, BST2&#x02013;ILT7 interaction might be bidirectional in a cancer environment, and the consequence of ILT7 engagement on BST2-expressing tumor cells should be investigated in the future.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title/><sec><title>Reagents and cells.</title><p>HEK293 cells were grown in high-glucose DME supplemented with 10% FBS, 50 U/ml penicillin, and 50 &#x000b5;g/ml streptomycin. Breast cancer cells and mouse 2B4 NFAT-GFP reporter cells (<xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>) were grown in RPMI 1640 medium supplemented with 10% FBS and antibiotics. NHDF and HUVEC cells (Lonza) were cultured in Clonetics Fibroblast Cell Medium FGM-2 and Endothelial Cell Basal medium, respectively, supplemented with growth factors following the manufacturer&#x02019;s recommendations. HaCaT cells were provided by S. Ullrich (M.D. Anderson Cancer Center, Houston, TX) and cultured in RPMI 1640 medium supplemented with 10% FBS and antibiotics. Namalwa cells were cultured as previously described (<xref ref-type="bibr" rid="bib9">Cao et al., 2007</xref>). Human TNF-&#x003b1; was purchased from Peprotech. IFN-&#x003b1; was purchased from Sigma-Aldrich.</p></sec><sec><title>ILT7 reporter cell assay.</title><p>ELISA plates were coated with 10 &#x000b5;g/ml of protein in PBS or at the concentration specified. 10<sup>5</sup> cancer cells or transfected HEK293 cells were seeded in 24-well plates the day before the experiment. After 10<sup>5</sup> NFAT-GFP reporter cells were added to the ELISA plate or the cell monolayer, the plates were spun at 100 <italic>g</italic> for 2 min. After overnight culture, cells were subjected to flow cytometric analysis to measure GFP expression.</p></sec><sec><title>BST2 activation of human primary pDCs.</title><p>The institutional review board for human research at the M.D. Anderson Cancer Center approved the use of human blood samples for this study. Primary human pDCs were isolated from blood using a negative selection kit (Miltenyi Biotech) and sorted by flow cytometry as CD3<sup>&#x02212;</sup>CD11c<sup>&#x02212;</sup>CD14<sup>&#x02212;</sup>CD15<sup>&#x02212;</sup>CD16<sup>&#x02212;</sup>CD19<sup>&#x02212;</sup>CD56<sup>&#x02212;</sup>CD4<sup>+</sup>CD123<sup>+</sup> cells. pDCs were preincubated with plate-bound control Fc protein or BST2-Fc protein captured with 10 &#x000b5;g/ml of F(ab)<sub>2</sub> goat anti&#x02013;human IgG Fc (Jackson ImmunoResearch Laboratories) on an ELISA plate for 30 min before stimulation with 0.2 &#x000b5;M of CpG 2216 (Sigma-Genosys) or heat-inactivated influenza virus PR8 at a multiplicity of infection (MOI) of 6. 18 h later, the supernatants were harvested and analyzed for cytokines, and the cells were lysed and RNA subjected to RT-PCR analysis, as previously described (<xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>). To neutralize ILT7 in this assay, pDCs were preincubated with 20 &#x000b5;g/ml of anti-ILT7 (clone 17.2; <xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>), washed, and then incubated with plate-bound Fc or BST2-Fc and stimulated with CpG. In parallel, control pDCs were preincubated with medium or 20 &#x000b5;g/ml of IgG1, washed, and stimulated similarly on Fc- or BST2-Fc&#x02013;coated plates. To perform pDC and BST2-transfectant cell co-culture, pDCs were preincubated with inactivated influenza virus (MOI = 8) for 30 min, and cells were pelleted by centrifugation for 5 min at 500 <italic>g</italic> and added to parent HEK293 or BST2-HA&#x02013;transfected HEK293 monolayers. Cells were packed briefly by centrifuging at 100 <italic>g</italic> for 2 min. 18 h later, the supernatants were harvested and analyzed for cytokine secretion. To study calcium influx, purified control Fc protein or BST2-Fc protein was incubated with pDCs in the presence of goat anti&#x02013;human Fc F(ab)<sub>2</sub> (Jackson ImmunoResearch Laboratories). Dye loading and flow cytometric analysis were performed as previously described (<xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>).</p></sec><sec><title>Anti&#x02013;ILT7-L mAb generation.</title><p>6&#x02013;8-wk-old BALB/c mice were immunized with T47D and MDA-MB-231 cells by the alternate footpad method (<xref ref-type="bibr" rid="bib8">Cao et al., 2006</xref>). Hybridoma clones secreting mAbs that specifically stained T47D cells, but not MDA-MB-231 cells, were expanded. They were further screened for their ability to block T47D-induced GFP expression from ILT7<sup>+</sup> reporter cells. mAbs 26F8 (IgG1) and 28G4 (IgG2a) were affinity purified and fluorochrome conjugated using mAb conjugation kits (Invitrogen).</p></sec><sec><title>cDNA library screening.</title><p>A library of human full-length cDNA clones was purchased from OriGene Technologies, Inc. Plasmid DNA was prepared using the Wizard plus miniprep kit (Promega). For transfection, HEK293 cells were seeded at 10<sup>4</sup> cells/well in 96-well plates. 0.6 &#x000b5;l of Fugene 6 (Roche) was added to 15 &#x000b5;l of Opti-MEM (Invitrogen) and mixed with 10 &#x000b5;l of DNA from individual cDNA clone. After 15 min at room temperature, the mixture was added to cells. 48 h later, cells were centrifuged at 200 <italic>g</italic> for 3 min before the media was removed. 5 &#x000b5;g/ml of mAbs 26F8 or 28G4 was added and mixed with Cy5-labeled goat anti-mIgG (Jackson ImmunoResearch Laboratories). Cells were incubated at room temperature for 2 h in the dark and analyzed by using a fluorometric microvolume assay technology 8100 HTS system (Applied Biosystems).</p></sec><sec><title>BST2 transfection and expression analysis.</title><p>HEK293 cells were transfected with an expression plasmid containing the full-length human BST2 cDNA (Open Biosystems) with lipofectamine (Invitrogen). 48 h later, cells were either lysed for Western blot analysis using a BST2-specific rabbit polyclonal antibody (FabGennix, Inc.) or subjected to staining with fluorochrome-conjugated anti&#x02013;ILT7-L mAbs. HEK293 cells stably expressing BST2-HA were transfected with pcDNA3-zeo-BST2-HA, selected with Zeocin, and sorted for high HA expression by flow cytometry.</p></sec><sec><title>Generation of recombinant ILT7 and BST2 fusion protein.</title><p>The extracellular domain of ILT7 or extracellular domain of BST2 (excluding GPI anchor) were cloned into an expression vector containing a mutated human Fc fragment (<xref ref-type="bibr" rid="bib1">Arase et al., 2002</xref>). HEK293 cells were transiently transfected with the expression plasmids or the empty vector to produce recombinant protein, which was purified by using a Protein A column (GE Healthcare). The extracellular domain of BST2 (excluding GPI anchor) was constructed as a GST-fusion protein, which was stably expressed in CHOK1SV cells and purified by glutathione&#x02013;Sepharose affinity chromatography (GE Healthcare).</p></sec><sec><title>Surface plasma resonance analysis.</title><p>Surface plasma resonance was performed using a Biacore 3000 (GE Healthcare). BST2-Fc and Fc were covalently immobilized onto flow cells of a CM5 sensor chip by amine coupling according to the manufacturer&#x02019;s instruction. ILT7-Fc, Fc, and 26F8 in 10 mM Hepes (pH 7.4), 150 mM NaCl, and 0.005% P20 were passed over the chip at 20 &#x000b5;l/min. To block the interactions between BST2 and ILT7, 26F8 (120 &#x000b5;g/ml), IgG1 (120 &#x000b5;g/ml), or buffer was injected over BST2-Fc&#x02013;coated sensor chip before injection of ILT7-Fc (120 &#x000b5;g/ml).</p></sec></sec></sec></body><back><ack><p>We thank David Son and Ran Zhang for excellent technical assistance and Dr. Margaret Kripke for critiques of the manuscript.</p><p>This work is supported by grants from the National Institutes of Health (AI068129 to L.L. Lanier, AI074809 to W. Cao, and AI 059718 to Y.-J. Liu). L.L. Lanier is an American Cancer Society Research Professor.</p><p>The authors have no conflicting financial interests.</p></ack><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arase</surname><given-names>H.</given-names></name><name><surname>Mocarski</surname><given-names>E.S.</given-names></name><name><surname>Campbell</surname><given-names>A.E.</given-names></name><name><surname>Hill</surname><given-names>A.B.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name></person-group><year>2002</year><article-title>Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors</article-title>.<source>Science.</source><volume>296</volume>:<fpage>1323</fpage>&#x02013;<lpage>1326</lpage><pub-id pub-id-type="pmid">11950999</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>S.</given-names></name><name><surname>Groh</surname><given-names>V.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Steinle</surname><given-names>A.</given-names></name><name><surname>Phillips</surname><given-names>J.H.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name><name><surname>Spies</surname><given-names>T.</given-names></name></person-group><year>1999</year><article-title>Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA</article-title>.<source>Science.</source><volume>285</volume>:<fpage>727</fpage>&#x02013;<lpage>729</lpage><pub-id pub-id-type="pmid">10426993</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benitez-Ribas</surname><given-names>D.</given-names></name><name><surname>Adema</surname><given-names>G.J.</given-names></name><name><surname>Winkels</surname><given-names>G.</given-names></name><name><surname>Klasen</surname><given-names>I.S.</given-names></name><name><surname>Punt</surname><given-names>C.J.A.</given-names></name><name><surname>Figdor</surname><given-names>C.G.</given-names></name><name><surname>de Vries</surname><given-names>I.J.M.</given-names></name></person-group><year>2006</year><article-title>Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4<sup>+</sup> T cells after Fc&#x003b3;RII-mediated uptake</article-title>.<source>J. Exp. Med.</source><volume>203</volume>:<fpage>1629</fpage>&#x02013;<lpage>1635</lpage><pub-id pub-id-type="pmid">16785312</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>P.</given-names></name><name><surname>Palucka</surname><given-names>A.K.</given-names></name><name><surname>Gill</surname><given-names>M.</given-names></name><name><surname>Pascual</surname><given-names>V.</given-names></name><name><surname>Banchereau</surname><given-names>J.</given-names></name></person-group><year>2001</year><article-title>Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus</article-title>.<source>Science.</source><volume>294</volume>:<fpage>1540</fpage>&#x02013;<lpage>1543</lpage><pub-id pub-id-type="pmid">11711679</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasius</surname><given-names>A.L.</given-names></name><name><surname>Cella</surname><given-names>M.</given-names></name><name><surname>Maldonado</surname><given-names>J.</given-names></name><name><surname>Takai</surname><given-names>T.</given-names></name><name><surname>Colonna</surname><given-names>M.</given-names></name></person-group><year>2006a</year><article-title>Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12</article-title>.<source>Blood.</source><volume>107</volume>:<fpage>2474</fpage>&#x02013;<lpage>2476</lpage><pub-id pub-id-type="pmid">16293595</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasius</surname><given-names>A.L.</given-names></name><name><surname>Giurisato</surname><given-names>E.</given-names></name><name><surname>Cella</surname><given-names>M.</given-names></name><name><surname>Schreiber</surname><given-names>R.D.</given-names></name><name><surname>Shaw</surname><given-names>A.S.</given-names></name><name><surname>Colonna</surname><given-names>M.</given-names></name></person-group><year>2006b</year><article-title>Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation</article-title>.<source>J. Immunol.</source><volume>177</volume>:<fpage>3260</fpage>&#x02013;<lpage>3265</lpage><pub-id pub-id-type="pmid">16920966</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>D.</given-names></name><name><surname>Trowsdale</surname><given-names>J.</given-names></name><name><surname>Allen</surname><given-names>R.</given-names></name></person-group><year>2004</year><article-title>The LILR family: modulators of innate and adaptive immune pathways in health and disease</article-title>.<source>Tissue Antigens.</source><volume>64</volume>:<fpage>215</fpage>&#x02013;<lpage>225</lpage><pub-id pub-id-type="pmid">15304001</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Rosen</surname><given-names>D.B.</given-names></name><name><surname>Ito</surname><given-names>T.</given-names></name><name><surname>Bover</surname><given-names>L.</given-names></name><name><surname>Bao</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>G.</given-names></name><name><surname>Yao</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name><name><surname>Liu</surname><given-names>Y.-J.</given-names></name></person-group><year>2006</year><article-title>Plasmacytoid dendritic cell&#x02013;specific receptor ILT7-Fc&#x003f5;RI&#x003b3; inhibits Toll-like receptor&#x02013;induced interferon production</article-title>.<source>J. Exp. Med.</source><volume>203</volume>:<fpage>1399</fpage>&#x02013;<lpage>1405</lpage><pub-id pub-id-type="pmid">16735691</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Rosen</surname><given-names>D.B.</given-names></name><name><surname>Bover</surname><given-names>L.</given-names></name><name><surname>Watanabe</surname><given-names>G.</given-names></name><name><surname>Bao</surname><given-names>M.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name><name><surname>Liu</surname><given-names>Y.-J.</given-names></name></person-group><year>2007</year><article-title>BDCA2/Fc&#x003f5;RI&#x003b3; complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells</article-title>.<source>PLoS Biol.</source><volume>5</volume>:<fpage>e248</fpage><pub-id pub-id-type="pmid">17850179</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carayannopoulos</surname><given-names>L.N.</given-names></name><name><surname>Naidenko</surname><given-names>O.V.</given-names></name><name><surname>Fremont</surname><given-names>D.H.</given-names></name><name><surname>Yokoyama</surname><given-names>W.M.</given-names></name></person-group><year>2002</year><article-title>Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D</article-title>.<source>J. Immunol.</source><volume>169</volume>:<fpage>4079</fpage>&#x02013;<lpage>4083</lpage><pub-id pub-id-type="pmid">12370332</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerwenka</surname><given-names>A.</given-names></name><name><surname>Bakker</surname><given-names>A.B.H.</given-names></name><name><surname>McClanahan</surname><given-names>T.</given-names></name><name><surname>Wagner</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Phillips</surname><given-names>J.H.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name></person-group><year>2000</year><article-title>Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice</article-title>.<source>Immunity.</source><volume>12</volume>:<fpage>721</fpage>&#x02013;<lpage>727</lpage><pub-id pub-id-type="pmid">10894171</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>T.L.</given-names></name><name><surname>Heikema</surname><given-names>A.P.</given-names></name><name><surname>Bjorkman</surname><given-names>P.J.</given-names></name></person-group><year>1999</year><article-title>The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18</article-title>.<source>Immunity.</source><volume>11</volume>:<fpage>603</fpage>&#x02013;<lpage>613</lpage><pub-id pub-id-type="pmid">10591185</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalupny</surname><given-names>N.J.</given-names></name><name><surname>Sutherland</surname><given-names>C.L.</given-names></name><name><surname>Lawrence</surname><given-names>W.A.</given-names></name><name><surname>Rein-Weston</surname><given-names>A.</given-names></name><name><surname>Cosman</surname><given-names>D.</given-names></name></person-group><year>2003</year><article-title>ULBP4 is a novel ligand for human NKG2D</article-title>.<source>Biochem. Biophys. Res. Commun.</source><volume>305</volume>:<fpage>129</fpage>&#x02013;<lpage>135</lpage><pub-id pub-id-type="pmid">12732206</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>M.</given-names></name><name><surname>Ishida</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Ohkawa</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Namiki</surname><given-names>S.</given-names></name><name><surname>Kotaki</surname><given-names>A.</given-names></name><name><surname>Arai</surname><given-names>N.</given-names></name><name><surname>Arai</surname><given-names>K.-i.</given-names></name><name><surname>Kamogawa-Schifter</surname><given-names>Y.</given-names></name></person-group><year>2008</year><article-title>SAGE library screening reveals ILT7 as a specific plasmacytoid dendritic cell marker that regulates type I IFN production</article-title>.<source>Int. Immunol.</source><volume>20</volume>:<fpage>155</fpage>&#x02013;<lpage>164</lpage><pub-id pub-id-type="pmid">18048391</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colonna</surname><given-names>M.</given-names></name><name><surname>Trinchieri</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.J.</given-names></name></person-group><year>2004</year><article-title>Plasmacytoid dendritic cells in immunity</article-title>.<source>Nat. Immunol.</source><volume>5</volume>:<fpage>1219</fpage>&#x02013;<lpage>1226</lpage><pub-id pub-id-type="pmid">15549123</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosman</surname><given-names>D.</given-names></name><name><surname>Fanger</surname><given-names>N.</given-names></name><name><surname>Borges</surname><given-names>L.</given-names></name><name><surname>Kubin</surname><given-names>M.</given-names></name><name><surname>Chin</surname><given-names>W.</given-names></name><name><surname>Peterson</surname><given-names>L.</given-names></name><name><surname>Hsu</surname><given-names>M.-L.</given-names></name></person-group><year>1997</year><article-title>A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules</article-title>.<source>Immunity.</source><volume>7</volume>:<fpage>273</fpage>&#x02013;<lpage>282</lpage><pub-id pub-id-type="pmid">9285411</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosman</surname><given-names>D.</given-names></name><name><surname>M&#x000fc;llberg</surname><given-names>J.</given-names></name><name><surname>Sutherland</surname><given-names>C.L.</given-names></name><name><surname>Chin</surname><given-names>W.</given-names></name><name><surname>Armitage</surname><given-names>R.</given-names></name><name><surname>Fanslow</surname><given-names>W.</given-names></name><name><surname>Kubin</surname><given-names>M.</given-names></name><name><surname>Chalupny</surname><given-names>N.J.</given-names></name></person-group><year>2001</year><article-title>ULBPs, novel MHC class I related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor</article-title>.<source>Immunity.</source><volume>14</volume>:<fpage>123</fpage>&#x02013;<lpage>133</lpage><pub-id pub-id-type="pmid">11239445</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della Bella</surname><given-names>S.</given-names></name><name><surname>Nicola</surname><given-names>S.</given-names></name><name><surname>Brambilla</surname><given-names>L.</given-names></name><name><surname>Riva</surname><given-names>A.</given-names></name><name><surname>Ferrucci</surname><given-names>S.</given-names></name><name><surname>Presicce</surname><given-names>P.</given-names></name><name><surname>Boneschi</surname><given-names>V.</given-names></name><name><surname>Berti</surname><given-names>E.</given-names></name><name><surname>Villa</surname><given-names>M.L.</given-names></name></person-group><year>2006</year><article-title>Quantitative and functional defects of dendritic cells in classic Kaposi&#x02019;s sarcoma</article-title>.<source>Clin. Immunol.</source><volume>119</volume>:<fpage>317</fpage>&#x02013;<lpage>329</lpage><pub-id pub-id-type="pmid">16527545</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desrosiers</surname><given-names>M.-P.</given-names></name><name><surname>Kielczewska</surname><given-names>A.</given-names></name><name><surname>Loredo-Osti</surname><given-names>J.C.</given-names></name><name><surname>Adam</surname><given-names>S.G.</given-names></name><name><surname>Makrigiannis</surname><given-names>A.P.</given-names></name><name><surname>Lemieux</surname><given-names>S.</given-names></name><name><surname>Pham</surname><given-names>T.</given-names></name><name><surname>Lodoen</surname><given-names>M.B.</given-names></name><name><surname>Morgan</surname><given-names>K.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name><name><surname>Vidal</surname><given-names>S.M.</given-names></name></person-group><year>2005</year><article-title>Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection</article-title>.<source>Nat. Genet.</source><volume>37</volume>:<fpage>593</fpage>&#x02013;<lpage>599</lpage><pub-id pub-id-type="pmid">15895081</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diefenbach</surname><given-names>A.</given-names></name><name><surname>Jensen</surname><given-names>E.R.</given-names></name><name><surname>Jamieson</surname><given-names>A.M.</given-names></name><name><surname>Raulet</surname><given-names>D.H.</given-names></name></person-group><year>2001</year><article-title>Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity</article-title>.<source>Nature.</source><volume>413</volume>:<fpage>165</fpage>&#x02013;<lpage>171</lpage><pub-id pub-id-type="pmid">11557981</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diefenbach</surname><given-names>A.</given-names></name><name><surname>Hsia</surname><given-names>J.K.</given-names></name><name><surname>Hsiung</surname><given-names>M.-Y.</given-names></name><name><surname>Raulet</surname><given-names>D.H.</given-names></name></person-group><year>2003</year><article-title>A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity</article-title>.<source>Eur. J. Immunol.</source><volume>33</volume>:<fpage>381</fpage>&#x02013;<lpage>391</lpage><pub-id pub-id-type="pmid">12645935</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>G.P.</given-names></name><name><surname>Koebel</surname><given-names>C.M.</given-names></name><name><surname>Schreiber</surname><given-names>R.D.</given-names></name></person-group><year>2006</year><article-title>Interferons, immunity and cancer immunoediting</article-title>.<source>Nat. Rev. Immunol.</source><volume>6</volume>:<fpage>836</fpage>&#x02013;<lpage>848</lpage><pub-id pub-id-type="pmid">17063185</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzionek</surname><given-names>A.</given-names></name><name><surname>Sohma</surname><given-names>Y.</given-names></name><name><surname>Nagafune</surname><given-names>J.</given-names></name><name><surname>Cella</surname><given-names>M.</given-names></name><name><surname>Colonna</surname><given-names>M.</given-names></name><name><surname>Facchetti</surname><given-names>F.</given-names></name><name><surname>Gunther</surname><given-names>G.</given-names></name><name><surname>Johnston</surname><given-names>I.</given-names></name><name><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name><surname>Nagasaka</surname><given-names>T.</given-names></name><etal/></person-group><year>2001</year><article-title>BDCA-2, a novel plasmacytoid dendritic cell&#x02013;specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon &#x003b1;/&#x003b2; induction</article-title>.<source>J. Exp. Med.</source><volume>194</volume>:<fpage>1823</fpage>&#x02013;<lpage>1834</lpage><pub-id pub-id-type="pmid">11748283</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebihara</surname><given-names>T.</given-names></name><name><surname>Masuda</surname><given-names>H.</given-names></name><name><surname>Akazawa</surname><given-names>T.</given-names></name><name><surname>Shingai</surname><given-names>M.</given-names></name><name><surname>Kikuta</surname><given-names>H.</given-names></name><name><surname>Ariga</surname><given-names>T.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Seya</surname><given-names>T.</given-names></name></person-group><year>2007</year><article-title>Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection</article-title>.<source>Int. Immunol.</source><volume>19</volume>:<fpage>1145</fpage>&#x02013;<lpage>1155</lpage><pub-id pub-id-type="pmid">17878262</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>A.</given-names></name><name><surname>Cella</surname><given-names>M.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Colonna</surname><given-names>M.</given-names></name></person-group><year>2005</year><article-title>Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44</article-title>.<source>Blood.</source><volume>106</volume>:<fpage>2076</fpage>&#x02013;<lpage>2082</lpage><pub-id pub-id-type="pmid">15941912</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilliet</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Y.-J.</given-names></name></person-group><year>2008</year><article-title>Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases</article-title>.<source>Nat. Rev. Immunol.</source><volume>8</volume>:<fpage>594</fpage>&#x02013;<lpage>606</lpage><pub-id pub-id-type="pmid">18641647</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gota</surname><given-names>C.</given-names></name><name><surname>Calabrese</surname><given-names>L.</given-names></name></person-group><year>2003</year><article-title>Induction of clinical autoimmune disease by therapeutic interferon-alpha</article-title>.<source>Autoimmunity.</source><volume>36</volume>:<fpage>511</fpage>&#x02013;<lpage>518</lpage><pub-id pub-id-type="pmid">14984028</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>T.</given-names></name><name><surname>Metzger</surname><given-names>J.</given-names></name><name><surname>Schmitz</surname><given-names>F.</given-names></name><name><surname>Heit</surname><given-names>A.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>T.</given-names></name><name><surname>Latz</surname><given-names>E.</given-names></name><name><surname>Wagner</surname><given-names>H.</given-names></name></person-group><year>2008</year><article-title>The DNA sugar backbone 2&#x02019; deoxyribose determines Toll-like receptor 9 activation</article-title>.<source>Immunity.</source><volume>28</volume>:<fpage>315</fpage>&#x02013;<lpage>323</lpage><pub-id pub-id-type="pmid">18342006</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamerman</surname><given-names>J.A.</given-names></name><name><surname>Ogasawara</surname><given-names>K.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name></person-group><year>2004</year><article-title>Cutting edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor</article-title>.<source>J. Immunol.</source><volume>172</volume>:<fpage>2001</fpage>&#x02013;<lpage>2005</lpage><pub-id pub-id-type="pmid">14764662</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>E.</given-names></name><name><surname>Wollenberg</surname><given-names>B.</given-names></name><name><surname>Rothenfusser</surname><given-names>S.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name><name><surname>Wellisch</surname><given-names>D.</given-names></name><name><surname>Mack</surname><given-names>B.</given-names></name><name><surname>Giese</surname><given-names>T.</given-names></name><name><surname>Gires</surname><given-names>O.</given-names></name><name><surname>Endres</surname><given-names>S.</given-names></name><name><surname>Hartmann</surname><given-names>G.</given-names></name></person-group><year>2003</year><article-title>Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer</article-title>.<source>Cancer Res.</source><volume>63</volume>:<fpage>6478</fpage>&#x02013;<lpage>6487</lpage><pub-id pub-id-type="pmid">14559840</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K.</given-names></name><name><surname>Taniguchi</surname><given-names>T.</given-names></name></person-group><year>2006</year><article-title>IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors</article-title>.<source>Nat. Rev. Immunol.</source><volume>6</volume>:<fpage>644</fpage>&#x02013;<lpage>658</lpage><pub-id pub-id-type="pmid">16932750</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarrossay</surname><given-names>D.</given-names></name><name><surname>Napolitani</surname><given-names>G.</given-names></name><name><surname>Colonna</surname><given-names>M.</given-names></name><name><surname>Sallusto</surname><given-names>F.</given-names></name><name><surname>Lanzavecchia</surname><given-names>A.</given-names></name></person-group><year>2001</year><article-title>Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells</article-title>.<source>Eur. J. Immunol.</source><volume>31</volume>:<fpage>3388</fpage>&#x02013;<lpage>3393</lpage><pub-id pub-id-type="pmid">11745357</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>N.</given-names></name><name><surname>Ho</surname><given-names>S.</given-names></name><name><surname>Antonenko</surname><given-names>S.</given-names></name><name><surname>de Waal Malefyt</surname><given-names>R.</given-names></name><name><surname>Kastelein</surname><given-names>R.A.</given-names></name><name><surname>Bazan</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Y.-J.</given-names></name></person-group><year>2001</year><article-title>Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens</article-title>.<source>J. Exp. Med.</source><volume>194</volume>:<fpage>863</fpage>&#x02013;<lpage>870</lpage><pub-id pub-id-type="pmid">11561001</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamphuis</surname><given-names>E.</given-names></name><name><surname>Junt</surname><given-names>T.</given-names></name><name><surname>Waibler</surname><given-names>Z.</given-names></name><name><surname>Forster</surname><given-names>R.</given-names></name><name><surname>Kalinke</surname><given-names>U.</given-names></name></person-group><year>2006</year><article-title>Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia</article-title>.<source>Blood.</source><volume>108</volume>:<fpage>3253</fpage>&#x02013;<lpage>3261</lpage><pub-id pub-id-type="pmid">16868248</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlhofer</surname><given-names>F.M.</given-names></name><name><surname>Ribaudo</surname><given-names>R.K.</given-names></name><name><surname>Yokoyama</surname><given-names>W.M.</given-names></name></person-group><year>1992</year><article-title>MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells</article-title>.<source>Nature.</source><volume>358</volume>:<fpage>66</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="pmid">1614533</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name></person-group><year>2006</year><article-title>Innate immune recognition of viral infection</article-title>.<source>Nat. Immunol.</source><volume>7</volume>:<fpage>131</fpage>&#x02013;<lpage>137</lpage><pub-id pub-id-type="pmid">16424890</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupzig</surname><given-names>S.</given-names></name></person-group><year>2003</year><article-title>Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology</article-title>.<source>Traffic.</source><volume>4</volume>:<fpage>694</fpage>&#x02013;<lpage>709</lpage><pub-id pub-id-type="pmid">12956872</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lande</surname><given-names>R.</given-names></name><name><surname>Gregorio</surname><given-names>J.</given-names></name><name><surname>Facchinetti</surname><given-names>V.</given-names></name><name><surname>Chatterjee</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.-H.</given-names></name><name><surname>Homey</surname><given-names>B.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.-H.</given-names></name><name><surname>Su</surname><given-names>B.</given-names></name><name><surname>Nestle</surname><given-names>F.O.</given-names></name><etal/></person-group><year>2007</year><article-title>Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide</article-title>.<source>Nature.</source><volume>449</volume>:<fpage>564</fpage>&#x02013;<lpage>569</lpage><pub-id pub-id-type="pmid">17873860</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname><given-names>L.L.</given-names></name></person-group><year>2008</year><article-title>Up on the tightrope: natural killer cell activation and inhibition</article-title>.<source>Nat. Immunol.</source><volume>9</volume>:<fpage>495</fpage>&#x02013;<lpage>502</lpage><pub-id pub-id-type="pmid">18425106</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Q.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Cooper</surname><given-names>M.D.</given-names></name></person-group><year>1998</year><article-title>Impairment of T and B cell development by treatment with a type I interferon</article-title>.<source>J. Exp. Med.</source><volume>187</volume>:<fpage>79</fpage>&#x02013;<lpage>87</lpage><pub-id pub-id-type="pmid">9419213</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.-J.</given-names></name></person-group><year>2005</year><article-title>IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors</article-title>.<source>Annu. Rev. Immunol.</source><volume>23</volume>:<fpage>275</fpage>&#x02013;<lpage>306</lpage><pub-id pub-id-type="pmid">15771572</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodoen</surname><given-names>M.</given-names></name><name><surname>Ogasawara</surname><given-names>K.</given-names></name><name><surname>Hamerman</surname><given-names>J.A.</given-names></name><name><surname>Arase</surname><given-names>H.</given-names></name><name><surname>Houchins</surname><given-names>J.P.</given-names></name><name><surname>Mocarski</surname><given-names>E.S.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name></person-group><year>2003</year><article-title>NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules</article-title>.<source>J. Exp. Med.</source><volume>197</volume>:<fpage>1245</fpage>&#x02013;<lpage>1253</lpage><pub-id pub-id-type="pmid">12756263</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshak-Rothstein</surname><given-names>A.</given-names></name><name><surname>Rifkin</surname><given-names>I.R.</given-names></name></person-group><year>2007</year><article-title>Immunologically active autoantigens: the role of Toll-Like receptors in the development of chronic inflammatory Disease</article-title>.<source>Ann. Rev. Immunol.</source><volume>25</volume>:<fpage>419</fpage>&#x02013;<lpage>441</lpage><pub-id pub-id-type="pmid">17378763</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Honda</surname><given-names>G.</given-names></name><name><surname>Muramatsu</surname><given-names>S.</given-names></name><name><surname>Matsuzaki</surname><given-names>O.</given-names></name><name><surname>Nagano</surname><given-names>Y.</given-names></name><name><surname>Doi</surname><given-names>T.</given-names></name><name><surname>Shimotohno</surname><given-names>K.</given-names></name><name><surname>Harada</surname><given-names>T.</given-names></name><name><surname>Nishida</surname><given-names>E.</given-names></name><etal/></person-group><year>2003</year><article-title>Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways</article-title>.<source>Oncogene.</source><volume>22</volume>:<fpage>3307</fpage>&#x02013;<lpage>3318</lpage><pub-id pub-id-type="pmid">12761501</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohty</surname><given-names>M.</given-names></name><name><surname>Jarrossay</surname><given-names>D.</given-names></name><name><surname>Lafage-Pochitaloff</surname><given-names>M.</given-names></name><name><surname>Zandotti</surname><given-names>C.</given-names></name><name><surname>Briere</surname><given-names>F.</given-names></name><name><surname>de Lamballeri</surname><given-names>X.-N.</given-names></name><name><surname>Isnardon</surname><given-names>D.</given-names></name><name><surname>Sainty</surname><given-names>D.</given-names></name><name><surname>Olive</surname><given-names>D.</given-names></name><name><surname>Gaugler</surname><given-names>B.</given-names></name></person-group><year>2001</year><article-title>Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment</article-title>.<source>Blood.</source><volume>98</volume>:<fpage>3750</fpage>&#x02013;<lpage>3756</lpage><pub-id pub-id-type="pmid">11739182</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohty</surname><given-names>M.</given-names></name><name><surname>Olive</surname><given-names>D.</given-names></name><name><surname>Gaugler</surname><given-names>B.</given-names></name></person-group><year>2004</year><article-title>Plasmacytoid DCs and cancer: a new role for an enigmatic cell</article-title>.<source>Trends Immunol.</source><volume>25</volume>:<fpage>397</fpage>&#x02013;<lpage>398</lpage><pub-id pub-id-type="pmid">15275634</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>F.</given-names></name><name><surname>Llano</surname><given-names>M.</given-names></name><name><surname>Bell&#x000f3;n</surname><given-names>T.</given-names></name><name><surname>Colonna</surname><given-names>M.</given-names></name><name><surname>Geraghty</surname><given-names>D.E.</given-names></name><name><surname>L&#x000f3;pez-Botet</surname><given-names>M.</given-names></name></person-group><year>1999</year><article-title>The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells</article-title>.<source>Eur. J. Immunol.</source><volume>29</volume>:<fpage>277</fpage>&#x02013;<lpage>283</lpage><pub-id pub-id-type="pmid">9933109</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neil</surname><given-names>S.J.D.</given-names></name><name><surname>Zang</surname><given-names>T.</given-names></name><name><surname>Bieniasz</surname><given-names>P.D.</given-names></name></person-group><year>2008</year><article-title>Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu</article-title>.<source>Nature.</source><volume>451</volume>:<fpage>425</fpage>&#x02013;<lpage>430</lpage><pub-id pub-id-type="pmid">18200009</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nice</surname><given-names>T.J.</given-names></name><name><surname>Coscoy</surname><given-names>L.</given-names></name><name><surname>Raulet</surname><given-names>D.H.</given-names></name></person-group><year>2009</year><article-title>Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress</article-title>.<source>J. Exp. Med.</source><volume>206</volume>:<fpage>287</fpage>&#x02013;<lpage>298</lpage><pub-id pub-id-type="pmid">19171762</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novak</surname><given-names>N.</given-names></name><name><surname>Allam</surname><given-names>J.-P.</given-names></name><name><surname>Hagemann</surname><given-names>T.</given-names></name><name><surname>Jenneck</surname><given-names>C.</given-names></name><name><surname>Laffer</surname><given-names>S.</given-names></name><name><surname>Valenta</surname><given-names>R.</given-names></name><name><surname>Kochan</surname><given-names>J.</given-names></name><name><surname>Bieber</surname><given-names>T.</given-names></name></person-group><year>2004</year><article-title>Characterization of Fc&#x003f5;RI-bearing CD123+ blood dendritic cell antigen-2+ plasmacytoid dendritic cells in atopic dermatitis</article-title>.<source>J. Allergy Clin. Immunol.</source><volume>114</volume>:<fpage>364</fpage>&#x02013;<lpage>370</lpage><pub-id pub-id-type="pmid">15316517</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtomo</surname><given-names>T.</given-names></name><name><surname>Sugamata</surname><given-names>Y.</given-names></name><name><surname>Ozaki</surname><given-names>Y.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><name><surname>Yoshimura</surname><given-names>Y.</given-names></name><name><surname>Kawai</surname><given-names>S.</given-names></name><name><surname>Koishihara</surname><given-names>Y.</given-names></name><name><surname>Ozaki</surname><given-names>S.</given-names></name><name><surname>Kosaka</surname><given-names>M.</given-names></name><name><surname>Hirano</surname><given-names>T.</given-names></name><name><surname>Tsuchiya</surname><given-names>M.</given-names></name></person-group><year>1999</year><article-title>Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells</article-title>.<source>Biochem. Biophys. Res. Commun.</source><volume>258</volume>:<fpage>583</fpage>&#x02013;<lpage>591</lpage><pub-id pub-id-type="pmid">10329429</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piqueras</surname><given-names>B.</given-names></name><name><surname>Connolly</surname><given-names>J.</given-names></name><name><surname>Freitas</surname><given-names>H.</given-names></name><name><surname>Palucka</surname><given-names>A.K.</given-names></name><name><surname>Banchereau</surname><given-names>J.</given-names></name></person-group><year>2006</year><article-title>Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors</article-title>.<source>Blood.</source><volume>107</volume>:<fpage>2613</fpage>&#x02013;<lpage>2618</lpage><pub-id pub-id-type="pmid">16317096</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000f6;ck</surname><given-names>J.</given-names></name><name><surname>Schneider</surname><given-names>E.</given-names></name><name><surname>Gr&#x000fc;n</surname><given-names>J.R.</given-names></name><name><surname>Gr&#x000fc;tzkau</surname><given-names>A.</given-names></name><name><surname>K&#x000fc;ppers</surname><given-names>R.</given-names></name><name><surname>Schmitz</surname><given-names>J.</given-names></name><name><surname>Winkels</surname><given-names>G.</given-names></name></person-group><year>2007</year><article-title>CD303 (BDCA-2) signals in plasmacytoid dendritic cells via a BCR-like signalosome involving Syk, Slp65 and PLC&#x003b3;2</article-title>.<source>Eur. J. Immunol.</source><volume>37</volume>:<fpage>3564</fpage>&#x02013;<lpage>3575</lpage><pub-id pub-id-type="pmid">18022864</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salio</surname><given-names>M.</given-names></name><name><surname>Cella</surname><given-names>M.</given-names></name><name><surname>Vermi</surname><given-names>W.</given-names></name><name><surname>Facchetti</surname><given-names>F.</given-names></name><name><surname>Palmowski</surname><given-names>M.J.</given-names></name><name><surname>Smith</surname><given-names>C.L.</given-names></name><name><surname>Shepherd</surname><given-names>D.</given-names></name><name><surname>Colonna</surname><given-names>M.</given-names></name><name><surname>Cerundolo</surname><given-names>V.</given-names></name></person-group><year>2003</year><article-title>Plasmacytoid dendritic cells prime IFN-&#x003b3;-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions</article-title>.<source>Eur. J. Immunol.</source><volume>33</volume>:<fpage>1052</fpage>&#x02013;<lpage>1062</lpage><pub-id pub-id-type="pmid">12672071</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarese</surname><given-names>E.</given-names></name><name><surname>Chae</surname><given-names>O.-w.</given-names></name><name><surname>Trowitzsch</surname><given-names>S.</given-names></name><name><surname>Weber</surname><given-names>G.</given-names></name><name><surname>Kastner</surname><given-names>B.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>Wagner</surname><given-names>H.</given-names></name><name><surname>Schmid</surname><given-names>R.M.</given-names></name><name><surname>Bauer</surname><given-names>S.</given-names></name><name><surname>Krug</surname><given-names>A.</given-names></name></person-group><year>2006</year><article-title>U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7</article-title>.<source>Blood.</source><volume>107</volume>:<fpage>3229</fpage>&#x02013;<lpage>3234</lpage><pub-id pub-id-type="pmid">16368889</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiroishi</surname><given-names>M.</given-names></name><name><surname>Kajikawa</surname><given-names>M.</given-names></name><name><surname>Kuroki</surname><given-names>K.</given-names></name><name><surname>Ose</surname><given-names>T.</given-names></name><name><surname>Kohda</surname><given-names>D.</given-names></name><name><surname>Maenaka</surname><given-names>K.</given-names></name></person-group><year>2006</year><article-title>Crystal Structure of the Human Monocyte-activating Receptor, &#x0201c;Group 2&#x0201d; Leukocyte Ig-like Receptor A5 (LILRA5/LIR9/ILT11)</article-title>.<source>J. Biol. Chem.</source><volume>281</volume>:<fpage>19536</fpage>&#x02013;<lpage>19544</lpage><pub-id pub-id-type="pmid">16675463</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisirak</surname><given-names>V.</given-names></name><name><surname>Gobert</surname><given-names>M.</given-names></name><name><surname>Renaudineau</surname><given-names>S.</given-names></name><name><surname>Menetrier-Caux</surname><given-names>C.</given-names></name><name><surname>Aspord</surname><given-names>C.</given-names></name><name><surname>Banchereau</surname><given-names>J.</given-names></name><name><surname>Palucka</surname><given-names>A.K.</given-names></name><name><surname>Blay</surname><given-names>J.-Y.</given-names></name><name><surname>Caux</surname><given-names>C.</given-names></name><name><surname>Berdriss-Vermare</surname><given-names>N.</given-names></name></person-group><year>2008</year><article-title>Breast tumor environment inhibits human plasmacytoid dendritic cells functions</article-title>. <comment><italic>In</italic> The 10th International Symposium on Dendritic Cells (Kobe, Japan). pp. P-4-03</comment></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>H.R.C.</given-names></name><name><surname>Heusel</surname><given-names>J.W.</given-names></name><name><surname>Mehta</surname><given-names>I.K.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Dorner</surname><given-names>B.G.</given-names></name><name><surname>Naidenko</surname><given-names>O.V.</given-names></name><name><surname>Iizuka</surname><given-names>K.</given-names></name><name><surname>Furukawa</surname><given-names>H.</given-names></name><name><surname>Beckman</surname><given-names>D.L.</given-names></name><name><surname>Pingel</surname><given-names>J.T.</given-names></name><etal/></person-group><year>2002</year><article-title>Recognition of a virus-encoded ligand by a natural killer cell activation receptor</article-title>.<source>Proc. Natl. Acad. Sci. USA.</source><volume>99</volume>:<fpage>8826</fpage>&#x02013;<lpage>8831</lpage><pub-id pub-id-type="pmid">12060703</pub-id></mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>L.-H.</given-names></name><name><surname>Goulet</surname><given-names>M.-L.</given-names></name><name><surname>Belanger</surname><given-names>S.</given-names></name><name><surname>Toyama-Sorimachi</surname><given-names>N.</given-names></name><name><surname>Fodil-Cornu</surname><given-names>N.</given-names></name><name><surname>Vidal</surname><given-names>S.M.</given-names></name><name><surname>Troke</surname><given-names>A.D.</given-names></name><name><surname>McVicar</surname><given-names>D.W.</given-names></name><name><surname>Makrigiannis</surname><given-names>A.P.</given-names></name></person-group><year>2008</year><article-title>Positive regulation of plasmacytoid dendritic cell function via Ly49Q recognition of class I MHC</article-title>.<source>J. Exp. Med.</source><volume>205</volume>:<fpage>3187</fpage>&#x02013;<lpage>3199</lpage><pub-id pub-id-type="pmid">19075287</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Avalos</surname><given-names>A.M.</given-names></name><name><surname>Mao</surname><given-names>S.-Y.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Senthil</surname><given-names>K.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Parroche</surname><given-names>P.</given-names></name><name><surname>Drabic</surname><given-names>S.</given-names></name><name><surname>Golenbock</surname><given-names>D.</given-names></name><name><surname>Sirois</surname><given-names>C.</given-names></name><etal/></person-group><year>2007</year><article-title>Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE</article-title>.<source>Nat. Immunol.</source><volume>8</volume>:<fpage>487</fpage>&#x02013;<lpage>496</lpage><pub-id pub-id-type="pmid">17417641</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treilleux</surname><given-names>I.</given-names></name><name><surname>Blay</surname><given-names>J.-Y.</given-names></name><name><surname>Bendriss-Vermare</surname><given-names>N.</given-names></name><name><surname>Ray-Coquard</surname><given-names>I.</given-names></name><name><surname>Bachelot</surname><given-names>T.</given-names></name><name><surname>Guastalla</surname><given-names>J.-P.</given-names></name><name><surname>Bremond</surname><given-names>A.</given-names></name><name><surname>Goddard</surname><given-names>S.</given-names></name><name><surname>Pin</surname><given-names>J.-J.</given-names></name><name><surname>Barthelemy-Dubois</surname><given-names>C.</given-names></name><name><surname>Lebecque</surname><given-names>S.</given-names></name></person-group><year>2004</year><article-title>Dendritic cell infiltration and prognosis of early stage breast cancer</article-title>.<source>Clin. Cancer Res.</source><volume>10</volume>:<fpage>7466</fpage>&#x02013;<lpage>7474</lpage><pub-id pub-id-type="pmid">15569976</pub-id></mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname><given-names>N.</given-names></name><name><surname>Goff</surname><given-names>D.</given-names></name><name><surname>Katsura</surname><given-names>C.</given-names></name><name><surname>Jorgenson</surname><given-names>R.L.</given-names></name><name><surname>Mitchell</surname><given-names>R.</given-names></name><name><surname>Johnson</surname><given-names>M.C.</given-names></name><name><surname>Stephens</surname><given-names>E.B.</given-names></name><name><surname>Guatelli</surname><given-names>J.</given-names></name></person-group><year>2008</year><article-title>The Interferon-Induced Protein BST-2 Restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein</article-title>.<source>Cell Host Microbe.</source><volume>3</volume>:<fpage>245</fpage>&#x02013;<lpage>252</lpage><pub-id pub-id-type="pmid">18342597</pub-id></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollmer</surname><given-names>J.</given-names></name><name><surname>Tluk</surname><given-names>S.</given-names></name><name><surname>Schmitz</surname><given-names>C.</given-names></name><name><surname>Hamm</surname><given-names>S.</given-names></name><name><surname>Jurk</surname><given-names>M.</given-names></name><name><surname>Forsbach</surname><given-names>A.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>Kelly</surname><given-names>K.M.</given-names></name><name><surname>Reeves</surname><given-names>W.H.</given-names></name><name><surname>Bauer</surname><given-names>S.</given-names></name><name><surname>Krieg</surname><given-names>A.M.</given-names></name></person-group><year>2005</year><article-title>Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8</article-title>.<source>J. Exp. Med.</source><volume>202</volume>:<fpage>1575</fpage>&#x02013;<lpage>1585</lpage><pub-id pub-id-type="pmid">16330816</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter-Yohrling</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Callahan</surname><given-names>M.</given-names></name><name><surname>Weber</surname><given-names>W.</given-names></name><name><surname>Morgenbesser</surname><given-names>S.</given-names></name><name><surname>Madden</surname><given-names>S.L.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Teicher</surname><given-names>B.A.</given-names></name></person-group><year>2003</year><article-title>Identification of genes expressed in malignant cells that promote invasion</article-title>.<source>Cancer Res.</source><volume>63</volume>:<fpage>8939</fpage>&#x02013;<lpage>8947</lpage><pub-id pub-id-type="pmid">14695211</pub-id></mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Kryczek</surname><given-names>I.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Daniel</surname><given-names>B.</given-names></name><name><surname>Cheng</surname><given-names>P.</given-names></name><name><surname>Mottram</surname><given-names>P.</given-names></name><name><surname>Curiel</surname><given-names>T.</given-names></name><name><surname>Lange</surname><given-names>A.</given-names></name><name><surname>Zou</surname><given-names>W.</given-names></name></person-group><year>2005</year><article-title>Plasmacytoid dendritic cells induce CD8+ regulatory t cells in human ovarian carcinoma</article-title>.<source>Cancer Res.</source><volume>65</volume>:<fpage>5020</fpage>&#x02013;<lpage>5026</lpage><pub-id pub-id-type="pmid">15958543</pub-id></mixed-citation></ref><ref id="bib69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>J.</given-names></name><name><surname>Bekisch</surname><given-names>B.</given-names></name><name><surname>Uerlich</surname><given-names>M.</given-names></name><name><surname>Haller</surname><given-names>O.</given-names></name><name><surname>Bieber</surname><given-names>T.</given-names></name><name><surname>Tuting</surname><given-names>T.</given-names></name></person-group><year>2005</year><article-title>Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions</article-title>.<source>Am. J. Clin. Pathol.</source><volume>124</volume>:<fpage>37</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="pmid">15923172</pub-id></mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>E.</given-names></name><name><surname>McVicar</surname><given-names>D.</given-names></name></person-group><year>2008</year><article-title>Paired receptor systems of the innate immune system</article-title>.<source>Curr. Protoc. Immunol.</source><comment>Appendix 1X</comment></mixed-citation></ref><ref id="bib68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W.</given-names></name><name><surname>Machelon</surname><given-names>V.</given-names></name><name><surname>Coulomb-L&#x02019;Hermin</surname><given-names>A.</given-names></name><name><surname>Borvak</surname><given-names>J.</given-names></name><name><surname>Nome</surname><given-names>F.</given-names></name><name><surname>Isaeva</surname><given-names>T.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Krzysiek</surname><given-names>R.</given-names></name><name><surname>Durand-Gasselin</surname><given-names>I.</given-names></name><name><surname>Gordon</surname><given-names>A.</given-names></name><etal/></person-group><year>2001</year><article-title>Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells</article-title>.<source>Nat. Med.</source><volume>7</volume>:<fpage>1339</fpage>&#x02013;<lpage>1346</lpage><pub-id pub-id-type="pmid">11726975</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p>Abbreviations used: BST2, bone marrow stromal cell antigen 2; ILT, Ig-like transcript; ITAM, immunoreceptor tyrosine-based activation motif; MOI, multiplicity of infection; pDC, plasmacytoid DC; TLR, Toll-like receptor.</p></fn></fn-group></back></article>